Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -10.87% and +21.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?